Literature DB >> 25834362

Amelanotic Acral Melanoma Associated with KIT Mutation and Vitiligo.

Young Jee Kim1, Jee-Bum Lee1, Seong-Jin Kim1, Seung-Chul Lee1, Young Ho Won1, Sook Jung Yun1.   

Abstract

Amelanotic acral melanoma is rare and difficult to diagnose, both clinically and pathologically. KIT mutations are frequently found in acral melanomas and are considered a risk factor for poor prognosis. The presence of vitiligo in melanoma has been reported, and KIT is thought to be partly responsible for the dysfunction and loss of melanocytes observed in vitiligo. We report a case of amelanotic subungual melanoma with multiple metastases that was associated with KIT mutation and vitiligo. An 85-year-old man presented with a 3-year history of a tender erythematous ulcerated tumor on the left third fingertip and developed hypopigmented patches on the face and trunk. Histopathological examination of the ulcerative tumor showed aggregates of tumor cells that were pleomorphic epithelioid cells. Immunohistochemical staining of the tumor cells was positive for S100, HMB45, and c-Kit. Histopathological findings from the hypopigmented patch on the face were consistent with vitiligo. Mutation analysis showed a KIT mutation in exon 17 (Y823D). The patient had metastasis to the brain, liver, bone, and both lungs. The patient refused chemotherapy, and died 3 months after the first visit.

Entities:  

Keywords:  Amelanotic melanoma; KIT mutation; Prognosis; Vitiligo

Year:  2015        PMID: 25834362      PMCID: PMC4377412          DOI: 10.5021/ad.2015.27.2.201

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  16 in total

1.  BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.

Authors:  Sun A Jin; Seung Min Chun; Yoo Duk Choi; Sun-Seog Kweon; Sung Taek Jung; Hyun Jeong Shim; Sook Jung Yun
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

2.  Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases.

Authors:  Wang L Cheung; Rishi R Patel; Aimee Leonard; Bahar Firoz; Shane A Meehan
Journal:  J Cutan Pathol       Date:  2011-11-03       Impact factor: 1.587

3.  Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients.

Authors:  C Kuchelmeister; G Schaumburg-Lever; C Garbe
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

4.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

5.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Authors:  Jun Guo; Lu Si; Yan Kong; Keith T Flaherty; Xiaowei Xu; Yanyan Zhu; Christopher L Corless; Li Li; Haifu Li; Xinan Sheng; Chuanliang Cui; Zhihong Chi; Siming Li; Mei Han; Lili Mao; Xuede Lin; Nan Du; Xiaoshi Zhang; Junling Li; Baocheng Wang; Shukui Qin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

6.  A novel KIT mutation results in piebaldism with progressive depigmentation.

Authors:  K A Richards; K Fukai; N Oiso; A S Paller
Journal:  J Am Acad Dermatol       Date:  2001-02       Impact factor: 11.527

Review 7.  Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?

Authors:  Anna Wankowicz-Kalinska; Caroline Le Poole; Rene van den Wijngaard; Walter J Storkus; Pranab K Das
Journal:  Pigment Cell Res       Date:  2003-06

8.  BRAF and KIT somatic mutations are present in amelanotic melanoma.

Authors:  Daniela Massi; Pamela Pinzani; Lisa Simi; Francesca Salvianti; Vincenzo De Giorgi; Maria A Pizzichetta; Francesco Mirri; Agostino Steffan; Claudio Orlando; Marco Santucci; Vincenzo Canzonieri
Journal:  Melanoma Res       Date:  2013-10       Impact factor: 3.599

9.  Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.

Authors:  Hui Han; Yang-Yang Yu; Yu-Hong Wang
Journal:  J Am Acad Dermatol       Date:  2008-11       Impact factor: 11.527

10.  Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses.

Authors:  Yoo Duk Choi; Seung Min Chun; Sun A Jin; Jee-Bum Lee; Sook Jung Yun
Journal:  J Am Acad Dermatol       Date:  2013-08-21       Impact factor: 11.527

View more
  3 in total

1.  A rare case of acral amelanotic melanoma, nodular type.

Authors:  Dereen Mohammed Saeed; Marylee Braniecki; John V Groth
Journal:  Int Wound J       Date:  2019-09-18       Impact factor: 3.315

2.  Expression of Epidermal c-Kit+ of Vitiligo Lesions Is Related to Responses to Excimer Laser.

Authors:  Oun Jae Park; Ji Su Han; Sang Hyung Lee; Chan-Sik Park; Chong Hyun Won; Mi Woo Lee; Jee Ho Choi; Sung Eun Chang
Journal:  Ann Dermatol       Date:  2016-07-26       Impact factor: 1.444

3.  Subungual Amelanotic Melanoma Masquerading as Onychomycosis.

Authors:  Ryan R Riahi; Philip R Cohen; Leonard H Goldberg
Journal:  Cureus       Date:  2018-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.